Show simple item record

dc.contributor.authorBjorkli, Christiana
dc.contributor.authorLouet, Claire
dc.contributor.authorFlo, Trude Helen
dc.contributor.authorHemler, Mary Elizabeth
dc.contributor.authorSandvig, Axel
dc.contributor.authorSandvig, Ioanna
dc.date.accessioned2022-03-02T08:46:58Z
dc.date.available2022-03-02T08:46:58Z
dc.date.created2021-02-05T14:31:02Z
dc.date.issued2021
dc.identifier.citationJournal of Alzheimer's Disease. 2021, 84 (4), 1781-1794.en_US
dc.identifier.issn1387-2877
dc.identifier.urihttps://hdl.handle.net/11250/2982309
dc.description.abstractBackground: Preclinical models of Alzheimer’s disease (AD) can provide valuable insights into the onset and progression of the disease, such as changes in concentrations of amyloid-β (Aβ) and tau in cerebrospinal fluid (CSF). However, such models are currently underutilized due to limited advancement in techniques that allow for longitudinal CSF monitoring. Objective: An elegant way to understand the biochemical environment in the diseased brain is intracerebral microdialysis, a method that has until now been limited to short-term observations, or snapshots, of the brain microenvironment. Here we draw upon patient-based findings to characterize CSF biomarkers in a commonly used preclinical mouse model for AD. Methods: Our modified push-pull microdialysis method was first validated ex vivo with human CSF samples, and then in vivo in an AD mouse model, permitting assessment of dynamic changes of CSF Aβ and tau and allowing for better translational understanding of CSF biomarkers. Results: We demonstrate that CSF biomarker changes in preclinical models capture what is observed in the brain; with a decrease in CSF Aβ observed when plaques are deposited, and an increase in CSF tau once tau pathology is present in the brain parenchyma. We found that a high molecular weight cut-off membrane allowed for simultaneous sampling of Aβ and tau, comparable to CSF collection by lumbar puncture in patients. Conclusion: Our approach can further advance AD and other neurodegenerative research by following evolving neuropathology along the disease cascade via consecutive sampling from the same animal and can additionally be used to administer pharmaceutical compounds and assess their efficacy.en_US
dc.language.isoengen_US
dc.publisherIOS Pressen_US
dc.titleIn Vivo Microdialysis in Mice Captures Changes in Alzheimer´s Disease Cerebrospinal Fluid Biomarkers Consistent with Developing Pathologyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holderThis version of the article will not be available due to copyright restrictions by IOS Pressen_US
dc.source.pagenumber1781-1794en_US
dc.source.volume84en_US
dc.source.journalJournal of Alzheimer's Diseaseen_US
dc.source.issue4en_US
dc.identifier.doi10.3233/JAD-210715
dc.identifier.cristin1887144
dc.relation.projectSamarbeidsorganet mellom Helse Midt-Norge og NTNU: 2018/42794en_US
dc.relation.projectNorges forskningsråd: 223255en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record